Skip to Content

CSL focused on creating medical breakthroughs

Fri 24 August 2018 09:20 AM Stocks to watch

Recent articles

Following the healthcare company’s FY 18 results, CSL’s Chief Financial Officer David Lamont and nabtrade’s Customer Insights Manager Vishal Teckchandani discuss:

  • Data insights on how nabtrade customers are investing in CSL,
  • Why investors should focus on the company's research & development activities,
  • If CSL has an appetite for a stock split, and
  • The CSL-112 trial, which is the largest trial undertaken by CSL for individuals who have suffered a heart attack. 

Note: The article referred to in the video can be viewed here.

 

netwealth

Netwealth Group Limited – Michael Heine (NWL:ASX)

Netwealth’s joint Managing Director shares with us what Netwealth does and how it differentiates itself from the competition.

6 March 2020 Stocks to watch
wesfarmerss

Wesfarmers Limited – Rob Scott (WES:ASX)

Wesfarmers Managing Director Rob Scott tells us more about the company, the opportunities and risks involved and why they’re not worried about tough economic periods.

6 March 2020 Stocks to watch
louise - future gen

Future Generation Investment Company Limited – Louise Walsh (FGX:ASX)

Future Generation Investment’s Louise Walsh tells us more about the company, how they differ to their competitors and how they’re giving back to the community.

6 March 2020 Stocks to watch
Bingo -

Bingo Industries Limited – Daniel Tartak (BIN:ASX)

Bingo’s Daniel Tartak tells us more about what they’re investing in and where they see growth opportunities.

6 March 2020 Stocks to watch